Drugs / 3,5-diiodothyropropionic acid
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00311987 | Apr 2006 → Apr 2007 | hyperlipidemia | Johns Hopkins University | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT00103519 | Dec 2004 → Dec 2006 | congestive heart failure | Titan Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00032643 | Jun 2004 → Dec 2006 | congestive heart failure | US Department of Veterans Affairs | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,5-diiodothyropropionic acid | “Then, each patient receives treatment with one of two doses of 3,5-diiodothyropropionic acid (DITPA) or placebo for six months.” NCT00032643 ↗ |
| Known as | DITPA | “3,5-Diiodothyropropionic acid (DITPA) therapy” NCT00311987 ↗ |
| Action | Activate | “suggesting partial agonistic actions” NCT00103519 ↗ |
| Modality | Small molecule | — CHEMBL2348292 ↗ |
| Route | Oral | “180 mg BID, orally” NCT00103519 ↗ |